Caplin Point Laboratories Limited

BSE: 524742 NSE: CAPLIPOINT
Caplin Point Laboratories Limited - pharma in Chennai, Tamil Nadu, India. FY 2026 financials & compliance.
CIN L24231TN1990PLC019053 Incorporated 16 April 1990 ROC Chennai HQ Chennai, Tamil Nadu, India
Active Listed - NSE: CAPLIPOINT · BSE: 524742 Public Limited Company pharma
Data last updated
Market Cap
₹19,374 Cr
CAPLIPOINT · NSE
Share Price
₹2,460.80
-3.45% today
Revenue
₹2,187 Cr
FY 2025-26 · +12.9% YoY
EBITDA
₹761 Cr
Margin 34.8%
Net Profit
₹626 Cr
FY 2025-26 · +16.8% YoY
P/E (TTM)
30.6x
P/B 6.0x
ROE
21.6%
ROCE 24.8%
Authorised capital
₹17 Cr
Registered with MCA

About Caplin Point Laboratories Limited

Data last updated:

Caplin Point Laboratories Limited is a public limited company based in Chennai, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 16 April 1990 and has been in existence for over 36 years.

The company is registered with the Registrar of Companies (ROC), Chennai, under CIN L24231TN1990PLC019053. Its GSTIN is 33AABCC2667F2ZY (Tamil Nadu). The company holds 7 GST registrations, of which 4 are active. Its shares are listed on BSE: 524742 and NSE: CAPLIPOINT.

The company has an authorised share capital of ₹17 Cr and a paid-up capital of ₹15.2 Cr. It was formerly known as Caplin Point Laboratories Private Limited. It is led by directors including Sridhar Ganesan (Managing Director) and Paarthipan Chingelput Chellappan.

Its last annual general meeting (AGM) was held on 22 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Chennai, Tamil Nadu.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,187.19 Cr, a growth of 12.9% compared to the previous year. For the same year it recorded a net profit of ₹626.2 Cr (net margin 28.6%) and EBITDA of ₹760.85 Cr (EBITDA margin 34.8%). The net worth stands at ₹3,586.42 Cr (up 25.8% YoY). Total assets are valued at ₹3,649.47 Cr (up 25.7% YoY).

The company has about 987 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.

The company is associated with 2 brands: Amaris Clinical and Caplin Point laboratories. As per MCA filings, the company has open charges of ₹10 Lakh and satisfied charges of ₹102.92 Cr on record. Court records list 56 cases involving the company, including 15 filed by the company and 33 filed against it; 7 cases are pending. The company has 14 deals on record (8 secondary share transfers, 5 market trades, 1 funding round), with disclosed funding of ₹222.3 Cr; the latest was in August 2024. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Pfizer Limited with revenue of ₹2,453.6 Cr.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website caplinpoint.net.

Company Details of Caplin Point Laboratories Limited
CIN L24231TN1990PLC019053
Registration Number 019053
Incorporation Date 16 April 1990
ROC Chennai
Listing Status Listed (BSE: 524742, NSE: CAPLIPOINT)
Company Status Active
Date of Last AGM 22 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Sridhar Ganesan Managing Director Komattu Chacko John Additional Director Paarthipan Chingelput Chellappan Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    caplinpoint.net
  • Social Media
  • Registered Address
    Ashvich Towers 3rd Floor No.3 Developed Plots Industrial Estates Per, Ungudi, Chennai, Tamil Nadu, India – 600096
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Caplin Point Laboratories Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Caplin Point Laboratories Limited report

Financials, compliance, directors, charges, ownership and filings for Caplin Point Laboratories Limited in one report.

Financials from 2015 Directors & ownership Charges & compliance

Business Activity of Caplin Point Laboratories Limited

The main business activity of Caplin Point Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Financials of Caplin Point Laboratories Limited FY 2025-26 filings available

Caplin Point Laboratories Limited reported revenue of ₹2,187.19 Cr (up 12.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,187 Cr
+12.9% YoY
EBITDA
₹761 Cr
+17.6% YoY
Profit After Tax
₹626 Cr
+16.8% YoY
Net Worth
₹3,586 Cr
+25.8% YoY
Total Assets
₹3,649 Cr
+25.7% YoY
Total Debt
₹4.61 Cr
-8.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1871,9371,6941,4671,2691,061863
Revenue growth+12.9%+14.4%+15.5%+15.5%+19.6%+23.0%-
EBITDA761647551441395329260
EBITDA margin+34.8%+33.4%+32.6%+30.1%+31.1%+31.0%+30.1%
Profit before tax803677564451386314269
Net profit626536456375299238211
Net profit margin+28.6%+27.7%+26.9%+25.6%+23.6%+22.4%+24.5%
EPS (₹)84.3770.5760.1849.5739.5632.0328.42
Balance sheet
Total assets3,6492,9042,3681,9281,5301,2371,009
Net worth3,5862,8502,3161,8801,4841,186948
Total debt4.615.021.975.482.1318.3938.61
Cash & bank621591553493463438223
Net working capital1,8171,5191,3251,0791,039879655
Cash flow
Cash from operations52343231827133726944.68
Cash from investing(582)(333)(319)(216)(377)(29.68)(54.33)
Cash from financing(46.46)(38.32)(38.07)(28.17)(40.68)(23.98)79.77
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue610600543534510502493483
Revenue growth (YoY)+19.6%+19.5%+10.1%+10.5%+11.2%---
Other income33.5528.3633.6830.3923.1725.8231.3620.77
EBITDA213204190189178168162165
EBITDA margin+35.0%+34.0%+34.9%+35.4%+34.8%+33.4%+32.9%+34.1%
Depreciation21.6218.8019.2818.4016.2917.0416.2016.76
Interest0.180.360.180.160.180.170.180.21
Profit before tax225213204201184177177168
Tax46.1340.5638.0340.7733.7031.3937.1937.65
Net profit179173166160151145140131
EPS (₹)23.2122.3121.5120.2520.0318.6918.1917.12
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue738752625529528483528
Revenue growth-1.9%+20.4%+18.3%+0.1%+9.4%-8.6%-
EBITDA338332287220220214207
EBITDA margin+45.8%+44.1%+45.9%+41.6%+41.6%+44.3%+39.2%
Profit before tax508442366293250210253
Net profit383340283233187152194
Net profit margin+51.9%+45.2%+45.2%+44.1%+35.4%+31.4%+36.7%
EPS (₹)52.1844.6737.3530.8624.7820.6526.13
Balance sheet
Total assets2,0581,7061,3941,143934763606
Net worth2,0501,7011,3901,140931759600
Total debt2.191.660.931.340.621.332.41
Cash & bank20621521627131634558.27
Net working capital490415347306455426257
Cash flow
Cash from operations20319611115723129587.01
Cash from investing(213)(139)(118)(85.67)(237)(3.90)(41.00)
Cash from financing(45.81)(38.10)(34.26)(30.42)(22.76)(3.47)(32.92)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue203191189175183174185208
Revenue growth (YoY)+11.2%+10.2%+2.2%-15.8%-1.7%---
Other income62.7961.0831.7359.2232.0341.2528.8343.01
Total expenses10910897.5099.3395.9698.57108110
EBITDA94.4183.5991.7275.8586.6175.0477.3998.16
EBITDA margin+46.5%+43.7%+48.5%+43.3%+47.4%+43.2%+41.8%+47.2%
Depreciation6.566.906.376.026.146.096.016.49
Interest0.050.050.070.050.040.040.040.02
Profit before tax151138117129112110100135
Tax30.2128.2229.7326.4126.5723.6625.4628.92

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue610600543534510502493483
Revenue growth (YoY)+19.6%+19.5%+10.1%+10.5%+11.2%---
Other income33.5528.3633.6830.3923.1725.8231.3620.77
EBITDA213204190189178168162165
EBITDA margin+35.0%+34.0%+34.9%+35.4%+34.8%+33.4%+32.9%+34.1%
Depreciation21.6218.8019.2818.4016.2917.0416.2016.76
Interest0.180.360.180.160.180.170.180.21
Profit before tax225213204201184177177168
Tax46.1340.5638.0340.7733.7031.3937.1937.65
Net profit179173166160151145140131
EPS (₹)23.2122.3121.5120.2520.0318.6918.1917.12
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1871,9371,6941,4671,2691,061863
Revenue growth+12.9%+14.4%+15.5%+15.5%+19.6%+23.0%-
Other income11696.4367.2156.0638.7523.5441.33
Total expenses1,4261,2911,1431,026875733603
Employee cost19918514413711510367.76
EBITDA761647551441395329260
EBITDA margin+34.8%+33.4%+32.6%+30.1%+31.1%+31.0%+30.1%
Depreciation72.7765.9653.4444.9946.9036.9731.62
Interest0.870.610.780.780.701.590.32
Profit before tax803677564451386314269
Tax15313610374.3677.3762.1954.38
Net profit626536456375299238211
Net profit margin+28.6%+27.7%+26.9%+25.6%+23.6%+22.4%+24.5%
EPS (₹)84.3770.5760.1849.5739.5632.0328.42
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital23223223223223223289.71
Reserves & surplus3,3552,6192,0841,6491,252954716
Shareholders' funds (net worth)3,5862,8502,3161,8801,4841,186948
Minority interest44.3835.9031.1226.7925.9517.548.66
Secured loans0.000.000.000.000.000.0015.33
Unsecured loans4.615.021.975.482.1318.3923.28
Total debt4.615.021.975.482.1318.3938.61
Total liabilities3,6492,9042,3681,9281,5301,2371,009
Assets
Gross block965859702480444423355
Net block580546453280287305272
Capital work in progress23414411722117.7313.8820.12
Investments85959037628188.9811.2060.79
Inventories429336363288227179238
Sundry debtors826632543394317279229
Cash & bank balances621591553493463438223
Loans & advances32426319616623810771.67
Total current assets2,2001,8231,6551,3421,2461,004762
Total current liabilities383304330263207125107
Net working capital1,8171,5191,3251,0791,039879655
Total assets3,6492,9042,3681,9281,5301,2371,009
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash199139178151232221151
Net cash from operating activities52343231827133726944.68
Net cash from investing activities(582)(333)(319)(216)(377)(29.68)(54.33)
Net cash from financing activities(46.46)(38.32)(38.07)(28.17)(40.68)(23.98)79.77
Net change in cash(105)60.75(38.86)26.80(80.81)21570.11
Closing cash621591553493463438223
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+12.9%+14.4%+15.5%+15.5%+19.6%+23.0%-
EBITDA growth+17.6%+17.3%+25.0%+11.8%+20.1%+26.4%-
PBT growth+18.6%+19.9%+25.1%+17.0%+23.0%+16.4%+18.8%
Net income growth+16.8%+17.6%+21.6%+25.4%+25.8%+12.6%-
Revenue CAGR (3Y)+14.3%+15.1%+16.9%+19.3%+25.1%+25.3%+29.1%
EBITDA CAGR (3Y)+19.9%+17.9%+18.8%+19.3%+19.4%+18.9%+27.7%
Profitability & leverage
Net income margin+29.7%+27.9%+27.2%+25.7%+24.3%+23.7%+24.9%
Return on capital employed+24.8%+26.0%+26.7%+26.6%+28.4%+28.4%+32.9%
Return on net worth+21.6%+22.9%+24.5%+25.7%+27.6%+27.3%+29.3%
Debt / equity0.000.000.000.000.010.030.02
Long-term debt / equity0.000.000.000.000.000.020.02
Interest cover0.130.100.160.200.200.550.14
Efficiency & per share
Fixed asset turnover2.402.482.863.172.932.732.76
Inventory turnover5.725.545.205.696.255.096.26
Debtors turnover3.003.303.624.134.264.184.44
EPS (₹)84.3770.5760.1849.5739.5632.0328.42
Dividend per share (₹)8.006.005.004.504.003.002.50
Book value per share (₹)443.40346.57276.38219.22167.20128.1296.68
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue203191189175183174185208
Revenue growth (YoY)+11.2%+10.2%+2.2%-15.8%-1.7%---
Other income62.7961.0831.7359.2232.0341.2528.8343.01
Total expenses10910897.5099.3395.9698.57108110
EBITDA94.4183.5991.7275.8586.6175.0477.3998.16
EBITDA margin+46.5%+43.7%+48.5%+43.3%+47.4%+43.2%+41.8%+47.2%
Depreciation6.566.906.376.026.146.096.016.49
Interest0.050.050.070.050.040.040.040.02
Profit before tax151138117129112110100135
Tax30.2128.2229.7326.4126.5723.6625.4628.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue738752625529528483528
Revenue growth-1.9%+20.4%+18.3%+0.1%+9.4%-8.6%-
Other income19513510699.0056.5518.6265.97
Total expenses401420338309308269321
Employee cost47.7252.1338.1136.6830.4726.5925.00
EBITDA338332287220220214207
EBITDA margin+45.8%+44.1%+45.9%+41.6%+41.6%+44.3%+39.2%
Depreciation25.4324.7727.0825.6525.7722.4419.65
Interest0.200.120.100.120.090.170.19
Profit before tax508442366293250210253
Tax11110282.0358.8962.4453.7155.49
Net profit383340283233187152194
Net profit margin+51.9%+45.2%+45.2%+44.1%+35.4%+31.4%+36.7%
EPS (₹)52.1844.6737.3530.8624.7820.6526.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital15.2015.2015.1915.1815.1615.1315.13
Reserves & surplus2,0351,6861,3751,125915744585
Shareholders' funds (net worth)2,0501,7011,3901,140931759600
Secured loans0.000.000.000.000.000.000.28
Unsecured loans2.191.660.931.340.621.332.13
Total debt2.191.660.931.340.621.332.41
Total liabilities2,0581,7061,3941,143934763606
Assets
Gross block422381318285269266228
Net block223205166157162183167
Capital work in progress9.3920.6427.7542.682.601.363.77
Investments1,047802584485265149196
Inventories85.6666.2686.2551.5342.8124.8722.37
Sundry debtors26617512988.2453.7398.46219
Cash & bank balances20621521627131634558.27
Loans & advances75.6758.0634.4240.3714133.2820.89
Total current assets633514465452554502321
Total current liabilities14399.3211814698.4276.5363.14
Net working capital490415347306455426257
Total assets2,0581,7061,3941,143934763606
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash99.6480.6412281.0134355.6142.52
Net cash from operating activities20319611115723129587.01
Net cash from investing activities(213)(139)(118)(85.67)(237)(3.90)(41.00)
Net cash from financing activities(45.81)(38.10)(34.26)(30.42)(22.76)(3.47)(32.92)
Net change in cash(55.55)19.00(41.38)41.01(29.06)28713.09
Closing cash20621521627131634558.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-1.9%+20.4%+18.3%+0.1%+9.4%-8.6%-
EBITDA growth+1.8%+15.6%+30.5%+0.1%+2.7%+3.4%-
PBT growth+14.9%+20.8%+24.8%+17.1%+19.2%-17.1%+24.9%
Net income growth+12.8%+20.3%+21.2%+24.6%+23.5%-21.8%-
Revenue CAGR (3Y)+11.8%+12.5%+9.0%+0.1%-0.6%+4.2%+15.6%
EBITDA CAGR (3Y)+15.4%+14.8%+10.3%+2.0%+5.2%+14.6%+30.2%
Profitability & leverage
Net income margin+53.7%+45.1%+45.4%+44.3%+35.6%+32.4%+37.4%
Return on capital employed+27.0%+28.5%+28.8%+28.2%+29.5%+30.7%+48.7%
Return on net worth+21.1%+22.0%+22.4%+22.6%+22.2%+23.0%+38.3%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover0.060.040.040.060.050.090.10
Efficiency & per share
Fixed asset turnover1.842.152.071.911.971.952.59
Inventory turnover9.729.879.0711.2115.6020.4423.00
Debtors turnover3.354.955.767.456.943.043.07
EPS (₹)52.1844.6737.3530.8624.7820.6526.13
Dividend per share (₹)8.006.005.004.504.003.002.50
Book value per share (₹)269.80223.81183.03150.19122.78100.2979.31
Want more history and ratios?
You're viewing the latest exchange-filed financials for Caplin Point Laboratories Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Peer Comparison of Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Pfizer Limited Listed₹2,453.6 Cr (FY 2025)••••••••3.0%••••Mumbai, Maharashtra, India
Marksans Pharma Limited Listed₹2,227.83 Cr (FY 2024)••••••••17.0%••••Mumbai, Maharashtra, India
Merck Life Science Private Limited₹2,200.06 Cr (FY 2025)••••••••7.0%••••Mumbai, Maharashtra, India
FDC Limited Listed₹2,198.78 Cr (FY 2025)••••••••8.0%••••Mumbai, Maharashtra, India
Caplin Point Laboratories Limited this company₹2,187.19 Cr (FY 2026)••••••••12.9%••••Chennai, Tamil Nadu, India
Unichem Laboratories Limited Listed₹2,146.29 Cr (FY 2025)••••••••18.0%••••Mumbai, Maharashtra, India
Bharat Serums and Vaccines Limited₹1,831.99 Cr (FY 2025)••••••••6.0%••••Thane, Maharashtra, India
Avet Lifesciences Private Limited₹1,801.29 Cr (FY 2025)••••••••20.0%••••Pune, Maharashtra, India
Astrazeneca Pharma India Limited Listed₹1,756.92 Cr (FY 2025)••••••••32.0%••••Bangalore, Karnataka, India
Leeford Healthcare Limited₹1,730.47 Cr (FY 2025)••••••••5.0%••••Ludhiana, Punjab, India
MSN Pharmachem Private Limited₹1,716.51 Cr (FY 2024)••••••••40.0%••••Hyderabad, Telangana, India

Peers are the five companies nearest above and the five nearest below Caplin Point Laboratories by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details of Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is audited by Brahmayya & Co for the financial year 2024.

NameStatusAppointment DateCessation Date
Brahmayya & CoLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Caplin Point Laboratories Limited

Caplin Point Laboratories has 9 current directors and 21 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Komattu Chacko John
Also directs: Caplin Steriles Limited
Additional Director05 Nov 20250 Years 11 MonthsCurrent
Paarthipan Chingelput Chellappan
Also directs: Caplin Steriles Limited, Caplin One Labs Limited, Indo-Latin American Chamber of Commerce & Industry Private Limited and 1 more
Director01 Oct 199333 Years 0 MonthsCurrent
Sridhar Ganesan
Also directs: Caplin Steriles Limited, Caplin One Labs Limited, Argus Salud Pharma LLP
Managing Director12 Feb 201412 Years 7 MonthsCurrent
Ramachandramurthy Nagendran
Also directs: Sriman Madhwa Sidhantaonnahini Permanent Nidhi Limited
Director29 Sep 20224 Years 0 MonthsCurrent
Singaram Deenadayalan
Also directs: Caplin One Labs Limited, Truscomp Private Limited, Ceo Skill Foundations Private Limited and 1 more
Director29 Sep 20224 Years 0 MonthsCurrent
Ashok Gorkey Partheeban
Also directs: May India Property Private Limited, Ashvich Infotek Private Limited
Additional Director05 Nov 20250 Years 11 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Shareholding Pattern of Caplin Point Laboratories Limited

Shareholding for the quarter ended Sep 2026: promoters hold 70.60%, foreign institutional investors hold 5.80%, domestic institutional investors hold 2.40% and retail and other public shareholders hold 21.20%.

Promoters: 70.60%DII (Domestic Institutional): 2.40%FII (Foreign Institutional): 5.80%Retail & Others: 21.20%
Sep 2026
QUARTER
70.60% Promoters
2.40% DII (Domestic Institutional)
5.80% FII (Foreign Institutional)
21.20% Retail & Others
Promoter holding - history
Now 70.60% · Sep 2026High 70.60% · Dec 2025Low 70.60% · Dec 2025
69%69.8%70.5%71.3%72%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 70.60%Mar 2026: 70.60%Jun 2026: 70.60%Sep 2026: 70.60%70.60%70.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters70.60%70.60%70.60%70.60%
Public29.40%29.40%29.40%29.40%

Charges & Borrowings of Caplin Point Laboratories Limited

Open charges
₹10 Lakh
Satisfied charges
₹102.92 Cr
Breakdown by lending institutions
Indian Overseas Bank₹0.10 Cr
Latest charge details
DateLenderAmountStatus
21 Jan 1994Indian Overseas Bank₹10 LakhOpen
02 May 2024Others₹7.6 CrSatisfied
28 Apr 2023Others₹10 CrSatisfied
30 Nov 2021Others₹7.6 CrSatisfied
23 Mar 2016Others₹80 LakhSatisfied

Total charge records: 18 View all charges

Deals & Funding of Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has 14 deals on record (8 secondary share transfers, 5 market trades, 1 funding round), with disclosed funding of ₹222.3 Cr; the latest was in August 2024.

Total deals
14
Secondary share transfers
8
Market trades
5
Funding round
1
Disclosed funding
₹222.3 Cr

Deals on record (5 of 14)

WhenDealAmountParties
Aug 2024Market trade₹75.36 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Aug 2024Market trade₹78.39 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Sep 2021Market trade₹34.64 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Jul 2021Market trade₹39.74 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Jul 2021Market trade₹42.19 CrBuyer: XTX Markets LLP
Seller: XTX Markets LLP
Premium access

Full deal history

All 14 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Associated Brands with Caplin Point Laboratories Limited

Caplin Point Laboratories operates two associated brands: Amaris Clinical and Caplin Point laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Caplin Point laboratories
Manufacturer of a pharmaceutical generics and biotech productscaplinpoint.net
Amaris Clinical
Clinical research, bioanalysis, and technical services are offered by Amaris Clinical.amarisclinical.com

Employees and EPFO Compliance at Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has a workforce of 987 employees as of Mar 29, 2025.

Employee count
987
Active EPFO establishments
1
Employee growth
12.93%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Group Structure of Caplin Point Laboratories Limited

Caplin Point Laboratories has 2 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

2
Subsidiary companies
1
Associated companies
Key Subsidiaries
Company NameCINShares Held
Caplin One Labs LimitedU24299TN2021PLC143869-
Caplin Steriles LimitedU24304TN2018PLC126270-

Showing major subsidiaries. Total: 2.

CIN History of Caplin Point Laboratories Limited

Caplin Point Laboratories has one previous CIN (Corporate Identification Number): L24231TN1990PTC019053. The current CIN is L24231TN1990PLC019053, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24231TN1990PLC019053Current
L24231TN1990PTC019053Previous

News related to Caplin Point Laboratories Limited

Recent Activity on Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has 43 board changes on record since 1993: 27 appointments and 16 cessations. The latest: Susan Mathew was appointed as Director on 31 Jan 2026.

Appointed
Susan Mathew was appointed as Director.
Appointed
Ashok Gorkey Partheeban was appointed as Additional Director.
Appointed
Komattu Chacko John was appointed as Additional Director.
Appointed
Partheeban Vivek Siddarth was appointed as Additional Director.
AGM
Caplin Point Laboratories Limited last Annual general meeting of members was held on 22 Sep 2025 as per latest MCA records.
Charges
A charge registered on 07 May 2007 via Charge ID 10052661 with The Catholic Syrian Bank Ltd was fully satisfied on 31 Jul 2025.
Charges
A charge registered on 28 Apr 2023 via Charge ID 100721464 with Others was fully satisfied on 04 Jun 2025.
Charges
A charge registered on 02 May 2024 via Charge ID 100925229 with Others was fully satisfied on 08 May 2025.
Filing
Caplin Point Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Chennai.
Ceased
Damodaran Sathyanarayanan ceased to be Director.
Appointed
Ranganathan Vijayaraghavan was appointed as Director.
Charges
A charge with Others amounted to Rs. 7.60 Cr with Charge ID 100925229 was registered on 02 May 2024.

75 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Caplin Point Laboratories Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Caplin Point Laboratories Limited

Premium access

MSME payment history

Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Caplin Point Laboratories Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Caplin Point Laboratories Limited

Caplin Point Laboratories has 7 GST registrations: 4 active and 3 cancelled or inactive.

Total GSTINs
7
Active
4
Cancelled / inactive
3
GSTINStateStatusRegistered on
33AABCC2667F2ZYTamil NaduActive01 Jul 2017
34AABCC2667F1ZXPuducherryActive01 Jul 2017
36AABCC2667F1ZTTelanganaActive01 Feb 2019
37AABCC2667F1ZRAndhra PradeshActive11 Nov 2022
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Caplin Point Laboratories Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Caplin Point Laboratories Limited

Caplin Point Laboratories is an active public limited company based in Chennai, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 16 April 1990 (36+ years old) and is registered under CIN L24231TN1990PLC019053. Listed on BSE: 524742 and NSE: CAPLIPOINT.

Caplin Point Laboratories reported revenue of ₹2,187.19 Cr for FY 2025-26 (up 12.9% YoY) based on consolidated financials.

Caplin Point Laboratories has 9 current directors:

The GSTIN of Caplin Point Laboratories is 33AABCC2667F2ZY, registered in Tamil Nadu. The company has 7 GST registrations in all, of which 4 are active and 3 are cancelled or inactive. Other active GSTINs include 34AABCC2667F1ZX (Puducherry), 36AABCC2667F1ZT (Telangana), 37AABCC2667F1ZR (Andhra Pradesh).

The CIN (Corporate Identification Number) of Caplin Point Laboratories is L24231TN1990PLC019053. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Caplin Point Laboratories is listed on both BSE (code: 524742) and NSE (symbol: CAPLIPOINT).

Caplin Point Laboratories has 56 court cases on record: 15 filed by the company and 33 filed against it. 7 are pending. Most are in the high courts.

Caplin Point Laboratories was incorporated on 16 April 1990, making it 36+ years old. It is registered with the Registrar of Companies, Chennai.

Caplin Point Laboratories has 14 deals on record (8 secondary share transfers, 5 market trades, 1 funding round), with disclosed funding of ₹222.3 Cr; the latest was in August 2024.

The peers of Caplin Point Laboratories by revenue are Pfizer Limited, Marksans Pharma Limited, Merck Life Science Private Limited, FDC Limited, Unichem Laboratories Limited and 5 more, all in the Pharma industry (Formulations).

Susan Mathew was appointed as Director on 31 Jan 2026. Ashok Gorkey Partheeban was appointed as Additional Director on 05 Nov 2025. Komattu Chacko John was appointed as Additional Director on 05 Nov 2025. Caplin Point Laboratories has 43 board changes on record in total.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available